RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) — About five years ago, the U.S. Food and Drug Administration (FDA) announced plans to toughen its guidelines around the development and oversight of regenerative medicine products. The goal was to make sure these therapies – which are growing rapidly in numbers – are safe and effective for consumers, while also providing a framework to encourage innovation … The changing regulatory landscape provided the impetus for Merakris Therapeutics to immediately engage with the FDA on its technology and the steps required to meet the new requirements, according to the Research-Triangle headquartered company’s CEO, Chris Broderick. Merakris was one of the first companies in its industry to do so … read more